Affimed N.V. rises 6.7% on ownership disclosure
- BySeeking Alpha-
Point72 Asset Management reports 5.0% passive stake in Affimed N.V. AFMD rises 6.7% after hours.Source.
Symbol | Exchange | Currency |
|---|
Point72 Asset Management reports 5.0% passive stake in Affimed N.V. AFMD rises 6.7% after hours.Source.
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks(Biotech Stocks Hitting 52-week Highs Feb. 2)Argenx SE – ADR (NASDAQ:...
Affimed N.V. (NASDAQ:AFMD) has surged ~10.6% in the premarket after announcing that it has entered a research collaboration with Roche (OTCQX:RHHBY) to study its innate cell...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Sell | Strong Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Sell | Strong Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 8.20 | 8.35 | 8.15 | -0.15 | -1.80% | 5.40M | Lagos | |||
| 31.50 | 31.50 | 30.90 | +0.50 | +1.61% | 7.69M | Lagos | |||
| 200.00 | 200.00 | 200.00 | -20.00 | -9.09% | 304.39K | Lagos | |||
| 25.65 | 25.85 | 25.50 | -0.15 | -0.58% | 48.10M | Lagos | |||
| 0.20 | 0.00 | 0.00 | +0.01 | +5.00% | 2.40M | Lagos | |||
| 0.36 | 0.00 | 0.00 | 0.00 | 0.00% | 0.00K | Lagos | |||
| 0.39 | 0.00 | 0.00 | -0.04 | -10.00% | 19.44M | Lagos | |||
| 5.05 | 5.05 | 5.05 | +0.150 | +3.06% | 23.84K | Lagos | |||
| 5.85 | 5.85 | 5.85 | +0.05 | +0.86% | 313.38K | Lagos | |||
| 5.25 | 5.25 | 5.25 | +0.45 | +9.38% | 396.82K | Lagos | |||
| 1.95 | 1.95 | 1.95 | +0.040 | +2.09% | 88.56K | Lagos | |||
| 0.50 | 0.00 | 0.00 | 0.0000 | 0.00% | 0.00K | Lagos | |||
| 1.20 | 1.20 | 1.20 | +0.08 | +7.14% | 2.90M | Lagos | |||
| 51.00 | 51.00 | 51.00 | -1.00 | -1.92% | 343.83K | Lagos | |||
| 7.75 | 7.95 | 7.75 | -0.25 | -3.13% | 2.13M | Lagos |
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.